These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21953755)

  • 21. Protein-Losing Enteropathy Following Fontan Palliation.
    Al Balushi A; Mackie AS
    Can J Cardiol; 2019 Dec; 35(12):1857-1860. PubMed ID: 31711823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation.
    John AS; Phillips SD; Driscoll DJ; Warnes CA; Cetta F
    Congenit Heart Dis; 2011; 6(6):653-6. PubMed ID: 21545466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Forty years of the Fontan operation: a failed strategy.
    Rychik J
    Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu; 2010; 13(1):96-100. PubMed ID: 20307870
    [No Abstract]   [Full Text] [Related]  

  • 24. Percutaneous management of a Fontan fenestration: in search for the ideal restriction-occlusion device.
    Boshoff DE; Brown SC; Degiovanni J; Stumper O; Wright J; Mertens L; Gewillig M
    Catheter Cardiovasc Interv; 2010 Jan; 75(1):60-5. PubMed ID: 19937791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fenestrated Amplatzer device for percutaneous creation of interatrial communication in patients after Fontan operation.
    Chatrath R; Cabalka AK; Driscoll DJ; Hagler DJ
    Catheter Cardiovasc Interv; 2003 Sep; 60(1):88-93. PubMed ID: 12929109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Original Surgical Procedure for the Treatment of Protein-Losing Enteropathy in Fontan Patients: Report of Two Midterm Successes.
    Brizard CP; Lane GK; Alex G; Cheung MM
    Circulation; 2016 Aug; 134(8):625-7. PubMed ID: 27550969
    [No Abstract]   [Full Text] [Related]  

  • 27. The Lymphatic Circulation in Adaptations to the Fontan Circulation.
    Menon S; Chennapragada M; Ugaki S; Sholler GF; Ayer J; Winlaw DS
    Pediatr Cardiol; 2017 Jun; 38(5):886-892. PubMed ID: 28210768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcatheter occlusion of azygos/hemiazygos vein in patients with systemic venous collateral development after the bidirectional Glenn procedure.
    Lu M; Wu W; Zhang G; So A; Zhao T; Xu Z; Zheng H; Xiangli W; Tian L; Liu S; Jiang S; Zhao S
    Cardiology; 2014; 128(3):293-300. PubMed ID: 24903599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of a new low profile Occlutech PLD device for closure of Fontan fenestrations.
    De Wolf D; Dessy H; Haas N
    Catheter Cardiovasc Interv; 2016 May; 87(6):E243-7. PubMed ID: 26526601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The failing Fontan: etiology, diagnosis and management.
    Goldberg DJ; Shaddy RE; Ravishankar C; Rychik J
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):785-93. PubMed ID: 21714609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fontan fenestration closure with Amplatzer Duct Occluder II device.
    McCrossan BA; Walsh KP
    Catheter Cardiovasc Interv; 2015 Apr; 85(5):837-41. PubMed ID: 25504151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of heparin in the treatment of protein-losing enteropathy after fontan operation for complex congenital heart disease.
    Kelly AM; Feldt RH; Driscoll DJ; Danielson GK
    Mayo Clin Proc; 1998 Aug; 73(8):777-9. PubMed ID: 9703306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extracardiac Fontan fenestration using the SafeSept transseptal guidewire and snare-controlled diabolo-shaped covered-stent placement.
    Casadonte JR; Wax DF; Gossett JG
    Catheter Cardiovasc Interv; 2016 Feb; 87(3):426-31. PubMed ID: 26105575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcatheter repair of Fontan baffle stenosis and fenestration in two patients using Cook Zenith aortic endografts.
    Madan N; Ellozy S; Love B
    J Invasive Cardiol; 2012 Feb; 24(2):E32-4. PubMed ID: 22294545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein-losing enteropathy after the modified fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement.
    Zellers TM; Brown K
    Pediatr Cardiol; 1996; 17(2):115-7. PubMed ID: 8833498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphatic obstruction and protein-losing enteropathy in patients with congenital heart disease.
    Meadows J; Gauvreau K; Jenkins K
    Congenit Heart Dis; 2008; 3(4):269-76. PubMed ID: 18715461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stents in the successful management of protein-losing enteropathy after fontan.
    Shahda S; Zahra M; Fiore A; Jureidini S
    J Invasive Cardiol; 2007 Oct; 19(10):444-6. PubMed ID: 17906348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transapical valve-in-valve implantation to treat a regurgitant mitral bioprothesis in a child with failing Fontan circulation.
    Moysich A; Kerst G; Akintürk H; Schranz D
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):e23-5. PubMed ID: 26048270
    [No Abstract]   [Full Text] [Related]  

  • 39. Reversal of protein-losing enteropathy with calcium replacement in a patient after Fontan operation.
    Kim SJ; Park IS; Song JY; Lee JY; Shim WS
    Ann Thorac Surg; 2004 Apr; 77(4):1456-7. PubMed ID: 15063295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent exacerbations of protein-losing enteropathy after initiation of growth hormone therapy in a Fontan patient controlled with spironolactone.
    Grattan MJ; McCrindle BW
    Congenit Heart Dis; 2010; 5(2):165-7. PubMed ID: 20412490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.